K1-70 Market Summary

Key Factors Driving K1-70 Growth

1. First-in-Class TSHR-Blocking Mechanism Targets the Root Cause of Graves' Disease

K1-70™ is the first clinical-stage monoclonal antibody specifically designed to block activation of the TSH receptor, thereby inhibiting the pathogenic autoantibodies responsible for Graves' disease. Unlike antithyroid drugs (e.g., methimazole), which suppress thyroid hormone synthesis without modifying the underlying autoimmune process, K1-70™ directly targets disease biology. This mechanism also provides a scientific rationale for treating both Graves' disease and TED with a single therapy.

2. Encouraging Phase I Clinical Data Demonstrating Safety and Pharmacodynamic Activity

Clinical development has produced encouraging early results. In the first-in-human Phase I study involving 18 Graves' disease patients, K1-70™ was generally well tolerated with no dose-limiting toxicities. The antibody produced dose-dependent reductions in thyroid hormone levels (FT3 and FT4) together with increases in TSH, confirming effective blockade of TSHR signaling. More recently, a Japanese Phase I study enrolled 12 patients across four dose cohorts (5, 25, 75 and 150 mg) and similarly reported no serious adverse events, favorable pharmacokinetics, and dose-dependent biological activity. These findings substantially de-risk further clinical development.

3. Early Evidence of Benefit in Thyroid Eye Disease

Beyond controlling hyperthyroidism, K1-70™ has demonstrated preliminary activity in TED. In the Japanese Phase I study, investigators reported improvement in proptosis in approximately 50% of treated eyes, together with marked reductions in thyroid-stimulating antibody (TSAb) levels. Although based on a small exploratory study, these findings suggest K1-70™ may address both thyroid dysfunction and orbital manifestations, differentiating it from conventional antithyroid medications.

4. Significant Unmet Need for Disease-Modifying Therapies

Current Graves' disease management relies on antithyroid drugs, radioactive iodine, or thyroidectomy, all of which have important limitations, including relapse, permanent hypothyroidism, or invasive treatment. K1-70™ has the potential to become a disease-modifying biologic that directly neutralizes the autoimmune driver rather than simply controlling hormone production. If larger clinical studies confirm durable remission with acceptable safety, K1-70™ could fill an important therapeutic gap for patients with recurrent or difficult-to-control Graves' disease and TED.

5. Expansion Opportunity Across Both Graves' Disease and TED

Because TSHR is central to the pathogenesis of both Graves' disease and TED, successful clinical development could support commercialization in two closely related autoimmune indications. This dual-indication strategy expands the addressable patient population while leveraging the same biological mechanism. The favorable pharmacokinetic profile observed in Phase I, including prolonged half-life at higher doses, also supports the potential for relatively infrequent dosing schedules, which may improve treatment adherence.

K1-70 Recent Developments

The 2025 Phase I study enrolled 12 Japanese patients across four dose cohorts and reported no serious adverse events, while noting mild-to-moderate treatment-emergent events such as headache and fatigue. The study also reported dose-dependent half-life increases, reductions in TSAb levels, and proptosis improvement in some eyes, supporting further study.

“K1-70 Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of K1-70 for potential indication like Graves ophthalmopathy in the 7MM. A detailed picture of K1-70’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the K1-70 for potential indications. The K1-70 market report provides insights about K1-70’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current K1-70 performance, future market assessments inclusive of the K1-70 market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of K1-70 sales forecasts, along with factors driving its market.

K1-70 Drug Summary

K1-70 is an investigational fully human monoclonal autoantibody that acts as a thyroid-stimulating hormone receptor (TSHR) antagonist and is being developed by Klinge Biopharma for the treatment of Graves’ disease, Graves’ hyperthyroidism, and thyroid eye disease (TED). Administered by intravenous infusion, K1-70 binds with high affinity to the extracellular domain of TSHR, competitively blocking stimulation by thyroid-stimulating autoantibodies (TSAb) as well as endogenous TSH. This targeted mechanism suppresses excessive thyroid hormone production and is expected to reduce the autoimmune signaling responsible for orbital inflammation and tissue expansion in TED. Unlike conventional immunosuppressive therapies, K1-70 directly targets the underlying pathogenic receptor driving disease. Preclinical studies demonstrated potent inhibition of TSHR signaling, and early clinical studies, including Phase I and Phase II trials, have shown an acceptable safety profile with preliminary evidence of improvements in thyroid function and ophthalmic manifestations. As of 2026, K1-70 remains an investigational therapy and has not yet received regulatory approval for any indication. The report provides K1-70’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the K1-70 Market Report

The report provides insights into:

• A comprehensive product overview including the K1-70 MoA, description, dosage and administration, research and development activities in potential indication like Graves ophthalmopathy.
• Elaborated details on K1-70 regulatory milestones and other development activities have been provided in K1-70 market report.
• The report also highlights K1-70‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The K1-70 market report also covers the patents information, generic entry and impact on cost cut.
• The K1-70 market report contains current and forecasted K1-70 sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The K1-70 market report also features the SWOT analysis with analyst views for K1-70 in potential indications.

Methodology

The K1-70 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

K1-70 Analytical Perspective by DelveInsight

• In-depth K1-70 Market Assessment

This K1-70 sales market forecast report provides a detailed market assessment of K1-70 for potential indication like Graves ophthalmopathy in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted K1-70 sales data uptil 2034.

• K1-70 Clinical Assessment

The K1-70 market report provides the clinical trials information of K1-70 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

K1-70 Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

K1-70 Market Potential & Revenue Forecast

• Projected market size for the K1-70 and its key indications
• Estimated K1-70 sales potential (K1-70 peak sales forecasts)
• K1-70 Pricing strategies and reimbursement landscape

K1-70 Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• K1-70 Market positioning compared to existing treatments
• K1-70 Strengths & weaknesses relative to competitors

K1-70 Regulatory & Commercial Milestones

• K1-70 Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

K1-70 Clinical Differentiation

• K1-70 Efficacy & safety advantages over existing drugs
• K1-70 Unique selling points

K1-70 Market Report Highlights

• In the coming years, the K1-70 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The K1-70 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence K1-70’s dominance.
• Other emerging products for Graves ophthalmopathy are expected to give tough market competition to K1-70 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of K1-70 in potential indications.
• Analyse K1-70 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted K1-70 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of K1-70 in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of K1-70? How strong is K1-70’s clinical and commercial performance?
• What is K1-70’s clinical trial status in each individual indications such as Graves ophthalmopathy and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the K1-70 Manufacturers?
• What are the key designations that have been granted to K1-70 for potential indications? How are they going to impact K1-70’s penetration in various geographies?
• What is the current and forecasted K1-70 market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of K1-70 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to K1-70 for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is K1-70? What is the duration of therapy and what are the geographical variations in cost per patient?